Recordbreaking BIO-Europe in Munich, but:...The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already the largest European … more ➔
Amyl Therapeutics bags €11m Series A ext...Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a €11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. more ➔
Evotech screens cancer candidates for Dewp...German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology. more ➔
Pierre Fabre SA licences immunotherapy fro...Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond. more ➔
Scotland boosts bio-based manufacturing wi...Biotech companies in Scotlands thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme. more ➔
Memo Therapeutics AG raises CHF25mSwiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage. more ➔
microRNA could offer a safe target in athe...Researchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls. more ➔
Cellectis and AstraZeneca in US$2.2bn dealAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. more ➔
Alfasigma SpA set to take over Galapagos p...Italian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos. more ➔
Abingworth raises $356m for new CCD fundRaising $356m through a new Clinical Co-Development Co-Investment Fund (CCD-CIF), Carlyle-subsidiary Abingworth has extended its capital base for late-stage clinical bio-pharma programmes. more ➔
